BioMedSyn

Orphalan SA is a Paris-based international company focused on the development and commercialization of innovative treatments for rare diseases, particularly those with limited or no therapeutic options. Founded in 2011, the company has successfully brought its trientine tetrahydrochloride product, marketed as Cuprior® / Cuvrior®, to over 30 countries for the treatment of Wilson disease. Orphalan is dedicated to placing patients at the center of its efforts, collaborating with scientific and medical communities to address unmet medical needs and improve the lives of individuals affected by rare and debilitating conditions. With a commitment to impactful and evidence-based solutions, Orphalan continues to expand its global presence and support for patients and their families.